What is the 13F Pro Quality Score for PETS?

13F Pro ranks PETMED EXPRESS INC (PETS) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View PETS's current score at https://13fpro.ai/company/PETS (free sign-up required for the full ranking).

Where does 13F Pro source PETS data?

All PETMED EXPRESS INC fundamentals and ownership data come directly from SEC EDGAR. PETMED EXPRESS INC files with the SEC under CIK 1040130. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is PETS in?

PETMED EXPRESS INC (PETS) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is PETS research updated on 13F Pro?

PETS's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

PETMED EXPRESS INC(PETS)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqsmall

Institutional-grade research for retail investors

SEC EDGAR: CIK 1040130 PETS stock profile & AI dashboard →

13F Pro Quality Score

18.0/100

Rank #2,817 of 2,962 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

3.6/100

Profitability

19.0/100

Balance Sheet

6.7/100

Earnings Quality

20.2/100

Free Cash Flow

14.1/100

Institutional Flow

5.9/100

Revenue Scale

21.5/100

Dilution Risk

64.8/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why PETS Scores 18/100

exact factor attribution · 2026-09-11

PETS's composite is held back by revenue growth and free cash flow. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Shareholder dilution

+0.7 pts

65th pct

Earnings growth

+0.4 pts

58th pct

Institutional flow

-2.2 pts

6th pct

Earnings quality

-3.0 pts

20th pct

Scale

-4.3 pts

22th pct

Capital efficiency

-4.3 pts

7th pct

Profitability

-4.7 pts

19th pct

Free cash flow

-5.4 pts

14th pct

Revenue growth

-9.3 pts

4th pct

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

PETS Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for PETMED EXPRESS INC (PETS), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores PETS at 18.0/100 on a 32-signal composite quality model, placing it at rank #2,817 of 2,962 stocks — the bottom half of the AI-ranked universe. Areas of concern include revenue growth (3.6) and institutional flow (5.9), which score below median versus the broader universe. Based on the latest XBRL financial filings (Q2 2026), PETMED EXPRESS INC reports quarterly revenue of $41.0M, net income of $-6.1M, free cash flow of $-8.3M. Top institutional holders of PETS by reported 13-F value include RENAISSANCE TECHNOLOGIES, VANGUARD CAPITAL MANAGEMENT, BlackRock, based on the most recent SEC filings. PETS trades on the Nasdaq exchange and files with the SEC under CIK 1040130. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate PETS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for PETMED EXPRESS INC directly from SEC EDGAR. PETMED EXPRESS INC's 13F Pro composite quality score has ranged between 17 and 34 since 2024, currently 18.0 — a declining long-term trajectory across 55 quarterly and live scoring snapshots.

✦

Fun facts about PETMED EXPRESS INC

Quirks, history, and lore behind PETS — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. direct-to-consumer company · listed on Nasdaq · headquartered in Florida · operates in a specialized retail niche.
2
The Numbers
Annual revenue in the range of $300 million — not a giant, but a consistent player in a market where Americans spend over $30 billion a year and climbing.
3
The History
Founded in the late 1990s, it was an early bet that consumers would happily skip the middleman and order a recurring necessity online and by phone rather than drive to a storefront.
4
The Secret
Its business is essentially a mail-order pharmacy — but the customers it's filling prescriptions for can't read the label themselves and are very good boys and girls.
5
The Lore
It competes fiercely with big-box retailers and vet clinics for a slice of every flea-and-tick treatment, heartworm pill, and arthritis medication dispensed to America's beloved four-legged dependents.
6
The Giveaway
The name literally says it all: medication delivered to your door for your dog or cat — and its ticker symbol is the most on-the-nose three letters on Wall Street.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q2 2026

$41.0M

Net Income

Q2 2026

$-6.1M

Free Cash Flow

Q2 2026

$-8.3M

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

-21.1% YoY

$179.0MFY 2026

FY23 $247.6MFY24 $274.1MFY25 $227.0MFY26 $179.0M

Net Income

-813.5% YoY

$-57.3MFY 2026

FY23 $5.1MFY24 $-7.5MFY25 $-6.3MFY26 $-57.3M

Operating Income

-3734.8% YoY

$-58.7MFY 2026

FY23 $6.1MFY24 $-8.2MFY25 $-1.5MFY26 $-58.7M

EPS (Diluted)

-813.3% YoY

$-2.74FY 2026

FY23 $0.25FY24 $-0.37FY25 $-0.30FY26 $-2.74

Total Assets

-45.4% YoY

$81.2MFY 2026

FY23 $167.5MFY24 $169.9MFY25 $148.7MFY26 $81.2M

Op. Cash Flow

-701.8% YoY

$-28.4MFY 2026

FY23 $27.8MFY24 $4.3MFY25 $4.7MFY26 $-28.4M

Free Cash Flow

-8256.7% YoY

$-33.0MFY 2026

FY23 $22.5MFY24 $-194.0KFY25 $-395.0KFY26 $-33.0M

Metric	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Revenue	$179.0M -21.1%	$227.0M -17.2%	$274.1M +10.7%	$247.6M -9.1%	$272.3M -10.3%	$303.6M
Net Income	$-57.3M -813.5%	$-6.3M +16.0%	$-7.5M -245.2%	$5.1M -72.5%	$18.7M -21.8%	$23.9M
Operating Income	$-58.7M -3734.8%	$-1.5M +81.3%	$-8.2M -234.9%	$6.1M -75.1%	$24.3M -20.4%	$30.5M
EPS (Diluted)	$-2.74 -813.3%	$-0.30 +18.9%	$-0.37 -248.0%	$0.25 -72.8%	$0.92 -22.7%	$1.19
Total Assets	$81.2M -45.4%	$148.7M -12.5%	$169.9M +1.4%	$167.5M -6.8%	$179.7M -4.2%	$187.5M
Operating Cash Flow	$-28.4M -701.8%	$4.7M +9.3%	$4.3M -84.5%	$27.8M +50.3%	$18.5M -53.8%	$40.1M
Free Cash Flow	$-33.0M -8256.7%	$-395.0K -103.6%	$-194.0K -100.9%	$22.5M +34.6%	$16.7M -55.5%	$37.6M

Get alerted when PETS's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for PETMED EXPRESS INC including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of PETS

RENAISSANCE TECHNOLOGIES LLC
$2.2M1,131,230 sh
VANGUARD CAPITAL MANAGEMENT LLC
$1.6M827,397 sh
BlackRock, Inc.
$1.1M568,255 sh
FEDERATED HERMES, INC.
$407.4K212,170 sh
GEODE CAPITAL MANAGEMENT, LLC
$391.9K204,075 sh
STEEL PARTNERS HOLDINGS L.P.
$371.8K193,664 sh
UBS Group AG
$265.6K138,330 sh
PRICE T ROWE ASSOCIATES INC /MD/
$250.0K129,933 sh
BRIDGEWAY CAPITAL MANAGEMENT, LLC
$232.4K121,048 sh
Rangeley Capital, LLC
$232.3K121,000 sh

Fund	Value	Shares
RENAISSANCE TECHNOLOGIES LLC	$2.2M	1,131,230
VANGUARD CAPITAL MANAGEMENT LLC	$1.6M	827,397
BlackRock, Inc.	$1.1M	568,255
FEDERATED HERMES, INC.	$407.4K	212,170
GEODE CAPITAL MANAGEMENT, LLC	$391.9K	204,075
STEEL PARTNERS HOLDINGS L.P.	$371.8K	193,664
UBS Group AG	$265.6K	138,330
PRICE T ROWE ASSOCIATES INC /MD/	$250.0K	129,933
BRIDGEWAY CAPITAL MANAGEMENT, LLC	$232.4K	121,048
Rangeley Capital, LLC	$232.3K	121,000

Companies Similar to PETS

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

SPRU

SPRUCE POWER HOLDING CORP

AI score

Shared smart-money ownership · 1 shared holders

STEEL PARTNERS HOLDINGS L.P.

RICK

RCI HOSPITALITY HOLDINGS, INC.

AI score

Shared smart-money ownership · 1 shared holders

STEEL PARTNERS HOLDINGS L.P.

SRTS

Sensus Healthcare, Inc.

AI score

Similar quality profile

MTEX

MANNATECH INC

AI score

Similar quality profile

BOOM

DMC Global Inc.

AI score

Similar quality profile · 1 shared holders

STEEL PARTNERS HOLDINGS L.P.

DRIO

DarioHealth Corp.

AI score

Similar quality profile

ACNT

ASCENT INDUSTRIES CO.

AI score

Similar quality profile

OPK

OPKO HEALTH, INC.

AI score

Similar quality profile · 1 shared holders

Formidable Asset Management, LLC

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put PETS on your watchlist

Track score changes the day PETMED EXPRESS INC files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is PETS a good stock to buy?

13F Pro's AI-powered analysis of PETMED EXPRESS INC (PETS) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for PETS are available on the PETS stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. PETS is classified as a small company.

Which hedge funds own PETS?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling PETS. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of PETMED EXPRESS INC's investment landscape.